Syndax Pharmaceuticals Inc Financials
This page shows Syndax Pharmaceuticals Inc (SNDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is finally meaningful, but Syndax still behaves like a cash-funded development company as commercial overhead expands.
From FY2024 to FY2025, revenue scaled from$23.7M to$172.4M , but that did not create cash conversion. Operating cash flow moved the other way, from-$274.9M to-$323.0M , showing that new sales arrived alongside a larger operating cost base rather than replacing external funding.
Spending mix is changing, not shrinking. SG&A rose to
The balance sheet now has a much thinner equity cushion: total equity fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Syndax Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Syndax Pharmaceuticals Inc has an operating margin of -158.4%, meaning the company retains $-158 of operating profit per $100 of revenue. This below-average margin results in a low score of 12/100, suggesting thin profitability after operating expenses. This is up from -1434.4% the prior year.
Syndax Pharmaceuticals Inc's revenue surged 627.8% year-over-year to $172.4M, reflecting rapid business expansion. This strong growth earns a score of 68/100.
Syndax Pharmaceuticals Inc has elevated debt relative to equity (D/E of 7.20), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 7/100, reflecting increased financial risk.
With a current ratio of 4.40, Syndax Pharmaceuticals Inc holds $4.40 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.
While Syndax Pharmaceuticals Inc generated -$323.0M in operating cash flow, capex of $187K consumed most of it, leaving -$323.2M in free cash flow. This results in a low score of 3/100, reflecting heavy capital investment rather than weak cash generation.
Syndax Pharmaceuticals Inc generates a -441.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 18/100. This is down from -110.7% the prior year.
Syndax Pharmaceuticals Inc scores -1.68, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.1B) relative to total liabilities ($465.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Syndax Pharmaceuticals Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Syndax Pharmaceuticals Inc generates $1.13 in operating cash flow (-$323.0M OCF vs -$285.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Syndax Pharmaceuticals Inc earns $-45514.0 in operating income for every $1 of interest expense (-$273.1M vs $6K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Syndax Pharmaceuticals Inc generated $172.4M in revenue in fiscal year 2025. This represents an increase of 627.8% from the prior year.
Syndax Pharmaceuticals Inc's EBITDA was -$267.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.5% from the prior year.
Syndax Pharmaceuticals Inc reported -$285.4M in net income in fiscal year 2025. This represents an increase of 10.5% from the prior year.
Syndax Pharmaceuticals Inc earned $-3.29 per diluted share (EPS) in fiscal year 2025. This represents an increase of 11.6% from the prior year.
Cash & Balance Sheet
Syndax Pharmaceuticals Inc generated -$323.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 17.6% from the prior year.
Syndax Pharmaceuticals Inc held $134.9M in cash against $0 in long-term debt as of fiscal year 2025.
Syndax Pharmaceuticals Inc had 87M shares outstanding in fiscal year 2025. This represents an increase of 2.0% from the prior year.
Margins & Returns
Syndax Pharmaceuticals Inc's operating margin was -158.4% in fiscal year 2025, reflecting core business profitability. This is up 1276.0 percentage points from the prior year.
Syndax Pharmaceuticals Inc's net profit margin was -165.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1180.7 percentage points from the prior year.
Syndax Pharmaceuticals Inc's ROE was -441.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 330.9 percentage points from the prior year.
Capital Allocation
Syndax Pharmaceuticals Inc invested $258.8M in research and development in fiscal year 2025. This represents an increase of 7.1% from the prior year.
Syndax Pharmaceuticals Inc invested $187K in capex in fiscal year 2025, funding long-term assets and infrastructure.
SNDX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $64.9M-5.3% | $68.5M+49.3% | $45.9M+20.8% | $38.0M+89.4% | $20.0M | N/A | $12.5M+257.1% | $3.5M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $58.8M-25.2% | $78.6M+39.7% | $56.3M-9.6% | $62.2M+1.0% | $61.6M | N/A | $71.0M+45.9% | $48.7M |
| SG&A Expenses | $37.6M-24.7% | $49.9M+11.2% | $44.9M+2.5% | $43.8M+6.8% | $41.0M | N/A | $31.1M+7.0% | $29.1M |
| Operating Income | -$34.2M+45.3% | -$62.5M-8.9% | -$57.4M+17.2% | -$69.4M+17.2% | -$83.8M | N/A | -$89.6M-20.7% | -$74.2M |
| Interest Expense | $0 | $0 | $0-100.0% | $4K+100.0% | $2K | N/A | $23K-48.9% | $45K |
| Income Tax | $0 | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Net Income | -$42.7M+37.2% | -$68.0M-12.0% | -$60.7M+15.5% | -$71.8M+15.3% | -$84.8M | N/A | -$84.1M-23.6% | -$68.1M |
| EPS (Diluted) | $-0.48 | N/A | $-0.70+15.7% | $-0.83+15.3% | $-0.98 | N/A | $-0.98-22.5% | $-0.80 |
SNDX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $472.7M-10.8% | $529.7M-4.0% | $551.8M-7.4% | $596.1M-7.0% | $640.7M-11.6% | $724.8M+70.2% | $425.8M-10.7% | $476.9M |
| Current Assets | $471.2M-10.8% | $528.1M-0.3% | $529.8M-0.3% | $531.7M-3.1% | $548.8M-9.0% | $603.1M+45.4% | $414.8M-7.0% | $446.1M |
| Cash & Equivalents | $130.9M-3.0% | $134.9M+15.5% | $116.8M+7.5% | $108.6M-29.5% | $154.0M-0.1% | $154.1M+15.8% | $133.0M+26.2% | $105.4M |
| Inventory | $34.9M+6.7% | $32.8M+31.0% | $25.0M+41.3% | $17.7M+279.4% | $4.7M+1174.3% | $366K | N/A | N/A |
| Accounts Receivable | N/A | $38.0M | N/A | N/A | N/A | $7.6M | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $431.0M-7.3% | $465.1M+6.6% | $436.4M-0.5% | $438.7M+3.1% | $425.6M-2.5% | $436.7M+635.4% | $59.4M+39.4% | $42.6M |
| Current Liabilities | $86.2M-28.3% | $120.1M+5.2% | $114.2M+1.1% | $113.0M+19.5% | $94.6M-8.7% | $103.5M+74.4% | $59.4M+39.8% | $42.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $41.6M-35.6% | $64.6M-44.0% | $115.4M-26.7% | $157.4M-26.8% | $215.1M-25.4% | $288.1M-21.4% | $366.4M-15.6% | $434.3M |
| Retained Earnings | -$1.5B-2.8% | -$1.5B-4.7% | -$1.4B-4.4% | -$1.4B-5.5% | -$1.3B-6.9% | -$1.2B-8.4% | -$1.1B-8.1% | -$1.0B |
SNDX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$50.3M+27.5% | -$69.5M+1.5% | -$70.5M+19.7% | -$87.8M+7.7% | -$95.2M-65.8% | -$57.4M+7.9% | -$62.3M+13.0% | -$71.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $38.4M-52.9% | $81.6M+12.6% | $72.4M+72.9% | $41.9M-55.5% | $94.1M+135.0% | -$269.0M-409.7% | $86.8M+40.6% | $61.8M |
| Financing Cash Flow | $7.9M+33.8% | $5.9M-5.8% | $6.3M+1039.4% | $551K-40.8% | $930K-99.7% | $347.4M+11114.5% | $3.1M+358.3% | $676K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SNDX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -52.7%+38.6pp | -91.3%+33.9pp | -125.2%+57.5pp | -182.7%+235.2pp | -417.9% | N/A | -716.6%+1403.8pp | -2120.5% |
| Net Margin | -65.8%+33.5pp | -99.3%+33.1pp | -132.4%+56.9pp | -189.3%+234.1pp | -423.3% | N/A | -673.0%+1271.7pp | -1944.7% |
| Return on Equity | -102.5%+2.7pp | -105.2%-52.6pp | -52.6%-7.0pp | -45.6%-6.2pp | -39.5% | N/A | -23.0%-7.3pp | -15.7% |
| Return on Assets | -9.0%+3.8pp | -12.8%-1.8pp | -11.0%+1.0pp | -12.0%+1.2pp | -13.2% | N/A | -19.8%-5.5pp | -14.3% |
| Current Ratio | 5.47+1.1 | 4.40-0.2 | 4.64-0.1 | 4.71-1.1 | 5.80-0.0 | 5.82-1.2 | 6.99-3.5 | 10.50 |
| Debt-to-Equity | 10.36+3.2 | 7.20+3.4 | 3.78+1.0 | 2.79+0.8 | 1.98+0.5 | 1.52+1.4 | 0.16+0.1 | 0.10 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Syndax Pharmaceuticals Inc's annual revenue?
Syndax Pharmaceuticals Inc (SNDX) reported $172.4M in total revenue for fiscal year 2025. This represents a 627.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Syndax Pharmaceuticals Inc's revenue growing?
Syndax Pharmaceuticals Inc (SNDX) revenue grew by 627.8% year-over-year, from $23.7M to $172.4M in fiscal year 2025.
Is Syndax Pharmaceuticals Inc profitable?
No, Syndax Pharmaceuticals Inc (SNDX) reported a net income of -$285.4M in fiscal year 2025, with a net profit margin of -165.6%.
What is Syndax Pharmaceuticals Inc's EBITDA?
Syndax Pharmaceuticals Inc (SNDX) had EBITDA of -$267.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Syndax Pharmaceuticals Inc's operating margin?
Syndax Pharmaceuticals Inc (SNDX) had an operating margin of -158.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Syndax Pharmaceuticals Inc's net profit margin?
Syndax Pharmaceuticals Inc (SNDX) had a net profit margin of -165.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Syndax Pharmaceuticals Inc's return on equity (ROE)?
Syndax Pharmaceuticals Inc (SNDX) has a return on equity of -441.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Syndax Pharmaceuticals Inc's free cash flow?
Syndax Pharmaceuticals Inc (SNDX) generated -$323.2M in free cash flow during fiscal year 2025. This represents a -17.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Syndax Pharmaceuticals Inc's operating cash flow?
Syndax Pharmaceuticals Inc (SNDX) generated -$323.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Syndax Pharmaceuticals Inc's total assets?
Syndax Pharmaceuticals Inc (SNDX) had $529.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Syndax Pharmaceuticals Inc's capital expenditures?
Syndax Pharmaceuticals Inc (SNDX) invested $187K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Syndax Pharmaceuticals Inc spend on research and development?
Syndax Pharmaceuticals Inc (SNDX) invested $258.8M in research and development during fiscal year 2025.
What is Syndax Pharmaceuticals Inc's current ratio?
Syndax Pharmaceuticals Inc (SNDX) had a current ratio of 4.40 as of fiscal year 2025, which is generally considered healthy.
What is Syndax Pharmaceuticals Inc's debt-to-equity ratio?
Syndax Pharmaceuticals Inc (SNDX) had a debt-to-equity ratio of 7.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Syndax Pharmaceuticals Inc's return on assets (ROA)?
Syndax Pharmaceuticals Inc (SNDX) had a return on assets of -53.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Syndax Pharmaceuticals Inc's cash runway?
Based on fiscal year 2025 data, Syndax Pharmaceuticals Inc (SNDX) had $134.9M in cash against an annual operating cash burn of $323.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Syndax Pharmaceuticals Inc's Altman Z-Score?
Syndax Pharmaceuticals Inc (SNDX) has an Altman Z-Score of -1.68, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Syndax Pharmaceuticals Inc's Piotroski F-Score?
Syndax Pharmaceuticals Inc (SNDX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Syndax Pharmaceuticals Inc's earnings high quality?
Syndax Pharmaceuticals Inc (SNDX) has an earnings quality ratio of 1.13x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Syndax Pharmaceuticals Inc cover its interest payments?
Syndax Pharmaceuticals Inc (SNDX) has an interest coverage ratio of -45514.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Syndax Pharmaceuticals Inc?
Syndax Pharmaceuticals Inc (SNDX) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.